Business Wire (Wed, 29-Jan 12:37 PM ET)
H.C. Wainwright Sticks to Their Hold Rating for Agenus (AGEN)
TipRanks (Mon, 27-Jan 11:35 AM ET)
Business Wire (Wed, 22-Jan 2:48 PM ET)
Business Wire (Wed, 18-Dec 7:30 AM ET)
Agenus Announces Strategic Realignment to Focus on Core Programs and Significantly Reduce Costs
Business Wire (Thu, 5-Dec 7:30 AM ET)
Agenus Secures $22 Million Mortgage and Announces Strategic Operational Realignment
Business Wire (Wed, 27-Nov 8:15 AM ET)
Business Wire (Tue, 12-Nov 7:00 AM ET)
Agenus to Present Compelling Data on Botensilimab and AGEN1721 at SITC 2024
Business Wire (Thu, 7-Nov 10:00 AM ET)
Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance
Business Wire (Thu, 7-Nov 7:00 AM ET)
Agenus to Provide Third Quarter 2024 Financial Report and Corporate Update
Business Wire (Tue, 5-Nov 7:30 AM ET)
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
Agenus trades on the NASDAQ stock market under the symbol AGEN.
As of January 29, 2025, AGEN stock price climbed to $3.61 with 320,209 million shares trading.
AGEN has a beta of 5.96, meaning it tends to be more sensitive to market movements. AGEN has a correlation of 0.23 to the broad based SPY ETF.
AGEN has a market cap of $85.24 million. This is considered a Micro Cap stock.
Last quarter Agenus reported $25 million in Revenue and -$3.08 earnings per share. This fell short of revenue expectation by $-8 million and missed earnings estimates by -$.75.
In the last 3 years, AGEN traded as high as $67.40 and as low as $2.50.
The top ETF exchange traded funds that AGEN belongs to (by Net Assets): IWM, VTI, VXF, IWN, VTWO.
AGEN has underperformed the market in the last year with a return of -72.8%, while the SPY ETF gained +24.9%. In the last 3 month period, AGEN fell short of the market, returning -18.1%, while SPY returned +4.0%. However, in the most recent 2 weeks AGEN has outperformed the stock market by returning +14.8%, while SPY returned +3.4%.
AGEN support price is $3.36 and resistance is $3.76 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AGEN shares will trade within this expected range on the day.